drugset / Trial / NCT02456844

Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients

NCT02456844

Phase 1 Completed 24 enrolled Bristol-Myers Squibb
Non-randomizedCrossoverOpen-labelBasic science

Summary

To study the Pharmacokinetics (PK) parameters of montelukast, flurbiprofen, midazolam, digoxin, pravastatin, and MTX when coadministered with BMS-986142.

Timeline

Start
2015-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986142 Small molecule
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Flurbiprofen Small molecule 50 mg Oral
Subject Methotrexate Small molecule 7.5 mg Oral
Subject Midazolam Small molecule 5 mg Oral
Subject Montelukast Other / unclassified 10 mg Oral
Subject Pravastatin Small molecule 40 mg Oral
Background Leucovorin Small molecule 15 mg Oral

Indications